A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours.

Horsley, Laura; Cummings, Jeffrey; Middleton, M; Ward, Timothy H; Backen, Alison C; Clamp, Andrew R; Dawson, Martin J; Farmer, H; Fisher, N; Halbert, G; Halford, S; Harris, A; Hasan, Jurjees; Hogg, P; Kumaran, Gireesh C; Little, R; Parker, G; Potter, Paula; Saunders, Mark P; Roberts, C; Shaw, Danielle; Smith, Nigel K; Smythe, J; Taylor, A; Turner, H; Watson, Y; Dive, Caroline; Jayson, Gordon C

Affiliation

Institute for Cancer Studies Christie Hospital NHS Foundation Trust, Wilmslow Road, Withington, Manchester, M20 4BX, UK.

Issue Date

2013-12

Metadata

Show full item record

Abstract

4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) is a water-soluble mitochondrial toxin that binds to adenine nucleotide translocase in the inner mitochondrial membrane, thereby targeting cell proliferation. This phase 1 study investigated safety, dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and pharmacokinetics (PK) of GSAO as a daily 1-h infusion for 5 days a week for 2 weeks in every three. Pharmacodynamics of GSAO was evaluated by dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) and circulating markers of angiogenesis.

Citation

A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. 2013, 72 (6):1343-52 Cancer Chemother Pharmacol

Journal

Cancer Chemotherapy and Pharmacology

URI

http://hdl.handle.net/10541/308799

DOI

10.1007/s00280-013-2320-9

PubMed ID

24141375

Type

Article

Language

ISSN

1432-0843

Collections

All Christie Publications